(3b)-3,17,21-trihydroxy-Pregn-5-en-20-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (3b)-3,17,21-trihydroxy-Pregn-5-en-20-one
• 英文别名: 1-(3,17-dihydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl)-2-hydroxyethanone
• 化学式: C₂₁H₃₂O₄
• 分子量: 348.5
• InChiKey: JNHJGXQUDOYJAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS
  申请人：Ripple Therapeutics Corporation

  公开号：US20210347809A1

  公开（公告）日：2021-11-11

  Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for the treatment of ocular diseases or disorders including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. Said compositions and methods comprise steroids and prostaglandins which demonstrate anti-inflammatory activity, intraocular pressure (IOP) lowering, and/or other desirable activities. Injection of said compositions in the eye provides therapeutic benefit to patients suffering from ocular disorders.

  本文描述了可加工的组合物，其中至少包含一个可在其自由形式下加工的成分。本文还描述了用于治疗眼部疾病或障碍的组合物和方法，包括青光眼、眼睑炎、眼部炎症、糖尿病性黄斑水肿、后部炎症、前部炎症、黄斑变性（如湿性黄斑变性（AMD）或干性AMD）、白内障手术后和视网膜静脉阻塞。所述组合物和方法包括表现出抗炎活性、降低眼内压力（IOP）和/或其他理想活性的类固醇和前列腺素。将所述组合物注射到眼中可为患有眼部障碍的患者提供治疗益处。
• Glass formulations and uses thereof
  申请人：Ripple Therapeutics Corporation

  公开号：US10632075B2

  公开（公告）日：2020-04-28

  The disclosure features pharmaceutical compositions formed from prodrug dimers for the extended delivery of a drug and for the treatment of a disease or condition.

  本公开的特征是由原药二聚体形成的药物组合物，用于延长给药时间和治疗疾病或病症。
• Gastrointestinal tract detection methods, devices and systems
  申请人：Progenity Inc.

  公开号：US10610104B2

  公开（公告）日：2020-04-07

  The present disclosure relates to gastrointestinal (GI) tract detection methods, devices and systems.

  本公开涉及胃肠道（GI）检测方法、装置和系统。
• Use of angiotensin II type 2 receptor agonist
  申请人：Vicore Pharma AB

  公开号：US11123329B1

  公开（公告）日：2021-09-21

  There is provided N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide, or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of respiratory virus-induced tissue damage. Such damage may be caused by coronaviruses, including severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. N-Butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide alleviate symptoms of diseases caused by those viruses (including coronavirus disease 2019 or COVID-19), such as cough, dyspnea, pneumonia, respiratory distress, respiratory failure and/or fibrosis of organs such as the lungs, the heart or the kidneys, and may thus prevent respiratory virus-induced morbidity and/or mortality. In particular, it has been found in a clinical study that the proportion of patients with COVID-19 needing oxygen treatment was significantly lower for patients that were administered N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide compared to placebo.

  提供了N-丁氧基羰基-3-(4-咪唑-1-基甲基苯基)-5-异丁基噻吩-2-磺酰胺或其药学上可接受的盐，用于呼吸道病毒引起的组织损伤的治疗方法。这种损伤可由冠状病毒引起，包括严重急性呼吸道综合征冠状病毒和严重急性呼吸道综合征冠状病毒。N-丁氧羰基-3-(4-咪唑-1-基甲基苯基)-5-异丁基噻吩-2-磺酰胺可减轻由这些病毒（包括冠状病毒病2019或COVID-19）引起的疾病症状，如咳嗽、呼吸困难、肺炎、呼吸窘迫、呼吸衰竭和/或肺部、心脏或肾脏等器官的纤维化，从而可预防呼吸道病毒引起的发病率和/或死亡率。特别是在一项临床研究中发现，与安慰剂相比，服用 N-丁酰氧羰基-3-（4-咪唑-1-基甲基苯基）-5-异丁基噻吩-2-磺酰胺的 COVID-19 患者需要氧气治疗的比例明显降低。
• Ingestible device and associated methods
  申请人：Progenity Inc.

  公开号：US11224364B2

  公开（公告）日：2022-01-18

  An ingestible device is disclosed which can produce spectral data of one or more analytes, as well as associated methods for characterizing the gastrointestinal tract of a subject which contains such analytes. Related kits and systems are also disclosed.

  本研究公开了一种可摄取的装置，它可以产生一种或多种分析物的光谱数据，还公开了相关方法，用于描述含有这些分析物的受试者的胃肠道特征。还公开了相关的试剂盒和系统。